Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
Reaction mass of pentasodium 2-{[4-chloro-6-(ethyl{3-[(2-sulfonatoethyl)sulfonyl]phenyl}amino)-1,3,5-triazin-2-yl]amino}-5-hydroxy-6-({2-sulfonato-4-[(4-sulfonatophenyl)diazenyl]phenyl}diazenyl)naphthalene-1,7-disulfonate and tetrasodium 2-[(4-chloro-6-{ethyl[3-(vinylsulfonyl)phenyl]amino}-1,3,5-triazin-2-yl)amino]-5-hydroxy-6-({2-sulfonato-4-[(4-sulfonatophenyl)diazenyl]phenyl}diazenyl)naphthalene-1,7-disulfonate
EC number: 459-580-2 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The test substance is considered as skin sensitiser in LLNA assay.
Key value for chemical safety assessment
Skin sensitisation
Link to relevant study records
- Endpoint:
- skin sensitisation: in vivo (LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 28 December, 2005 to 22 March 2006
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 429 (Skin Sensitisation: Local Lymph Node Assay)
- Deviations:
- not specified
- Qualifier:
- according to guideline
- Guideline:
- other: Commission Directive 2004/73/EC, B.42: Skin Sensitization: Local Lymph Node Assay, 29 April 2004.
- GLP compliance:
- yes (incl. QA statement)
- Type of study:
- mouse local lymph node assay (LLNA)
- Specific details on test material used for the study:
- Identity: FAT 40824/A
Batch: Red ROE 805 BOP 04/05
Appearance: dark red powder
Purity: Organic part (Na-salt): approx. 82 %; Main component 1 : approx. 36.2 %; Main component 2: approx. 27.5 %; Oligomers: 10%
Expiration date: 01 October 2010
Storage: At room temperature at about 20°C in a desiccator (hygroscopic) - Species:
- mouse
- Strain:
- CBA
- Sex:
- female
- Details on test animals and environmental conditions:
- TEST ANIMALS
Test system: Mice, CBA/CaHsdRcc(SPF)
Source: RCC Ltd Laboratory Animal Service CH-4414 Füllinsdorf / Switzerland
Number of animals for the pre-test (non-GLP): 3 females
Number of animals for the main study: 16 females
Number of test groups: 3
Number of negative control group: 1
Age: 8-12 weeks (beginning of acclimatization)
Body weight: 16 g - 24 g (ordered)
Acclimatization: Under test conditions after health examination. Only animals without any visible signs of illness were used for the study.
Accommodation: Individual in Makrolon type-2 cages with standard softwood bedding ("Lignocel", Schill AG, CH-4132 Muttenz).
Diet: Pelleted standard Kliba 3433, batch no. 63/05 mouse maintenance diet (Provimi Kliba AG, CH-4303 Kaiseraugst) available ad libitum.
Water: Community tap water from Itingen, available ad libitum.
ENVIRONMENTAL CONDITIONS
Standard Laboratory Conditions. Air-conditioned with ranges for room temperature 22 ±3 °C, relative humidity 30 - 70 % and 10 - 15 air changes per hour. Room temperature and humidity were monitored continuously and values outside of these ranges occasionally occurred, usually following room cleaning. These transient variations are considered not to have any influence on the study and, therefore, these data are not reported but are retained at RCC. There was a 12 hour fluorescent light / 12 hour dark cycle with at least 8 hours music during the light period. - Vehicle:
- dimethylformamide
- Remarks:
- N,N-dimethylformamide (DMF)
- Concentration:
- 2.5 %, 5 % and 10 % in N,N-dimethylformamide (DMF)
- No. of animals per dose:
- Number of animals per group: 4 females (nulliparous and non-pregnant)
- Details on study design:
- TEST ITEM FORMULATIONS PREPARATION
The test item was placed into a volumetric flask on a tared Mettler balance and the vehicle N,N-dimethylformamide (DMF) was quantitatively added. The weight/volume (w/v) dilutions were prepared individually using a magnetic stirrer as homogenizer. Test item formulations were made freshly before each dosing occasion and no more than 4 hours prior to application to the ears.
TOPICAL APPLICATION
Each test group of mice was treated by topical (epidermal) application to the dorsal surface of each ear lobe (left and right) with the test item at concentrations of 2.5 %, 5 % and 10 % in N,N-dimethylformamide (DMF). The application volume, 25µI, was spread over the entire dorsal surface ( 0 - 8 mm) of each ear lobe once daily for three consecutive days. A further group of mice was treated with an equivalent volume of the relevant vehicle alone (control animals).
ADMINISTRATION OF 3H-METHYL THYMIDINE
Five days after the first topical application, all mice were administered 250 µI of 78.27 µCi/ml 3HTdR (equal to 19.6 µCi 3HTdR) by intravenous injection via a tail vein.
DETERMINATION OF INCORPORATED 3HTDR
Approximately five hours after treatment with 3HTdR all mice were euthanized by inhalation of CO2(dry ice).
The draining lymph nodes were rapidly excised and pooled for each experimental group (8 nodes per group). Single cell suspensions (phosphate buffered saline) of pooled lymph node cells were prepared by gentle mechanical disaggregation through stainless steel gauze (200 /vm mesh size). After washing twice with phosphate buffered saline (approx. 10 ml) the lymph node cells were resuspended in 5 % trichloroacetic acid (approx. 3 ml) and incubated at approximately +4 °C for at least 18 hours for precipitation of macromolecules. The precipitates were then resuspended in 5 % trichloroacetic acid (1 ml) and transferred to glass scintillation vials with 10 ml of 'Irga-Safe Plus' scintillation liquid and thoroughly mixed.
The level of 3HTdR incorporation was then measured on a ß-scintillation counter. Similarly, background 3HTdR levels were also measured in two 1 ml-aliquots of 5 % trichloroacetic acid. The ß-scintillation counter expresses 3HTdR incorporation as the number of radioactive disintegrations per minute (dpm).
OBSERVATIONS
In addition to the sensitizing reactions the following observations and data were recorded during the test and observation period:
Mortality / Viability: Once daily from acclimatization start to the termination of in-life phase.
Body weights: On the test day 1 (prior to the 1st application) and on the test day 6.
Clinical signs (local / systemic): Once daily on the day of animals delivery and from test day 1 (after the 1st application) to the termination of
in-life phase. - Positive control substance(s):
- other: ALPHA-HEXYLCINNAMALDEHYDE
- Statistics:
- The mean values and standard deviations were calculated in the body weight tables. Body weights were recorded on-line in RCC-TOX LIMS. Clinical signs were compiled directly into the RCC computer system.
- Positive control results:
- STIMULATION INDICES of 2.9, 3.9 and 8.7 were determined with the test item at concentrations of 5 %, 10 % and 25 % (w/v), respectively, in acetone:olive oil, 4:1 (v/v). The positive control item ALPHA-HEXYLCINNAMALDEHYDE showed an allergenic potential, and an EC3 value of 5.5 % (w/v) was derived.
- Parameter:
- SI
- Value:
- 5
- Test group / Remarks:
- Group 2 (test item concentration (w/v):- 2.5)
- Parameter:
- SI
- Value:
- 3.1
- Test group / Remarks:
- Group 3 (test item concentration (w/v):- 5)
- Parameter:
- SI
- Value:
- 4.7
- Test group / Remarks:
- Group 4 (test item concentration (w/v):- 10)
- Interpretation of results:
- Category 1 (skin sensitising) based on GHS criteria
- Conclusions:
- In this study Stimulation indices of 5.0, 3.1 and 4.7 were determined with the test item at concentrations of 2.5 %, 5 % and 10 %, respectively, in N,N-dimethylformamide (DMF). FAT 40824/A was therefore found to be a skin sensitizer in the LLNA.
- Executive summary:
A GLP compliant LLNA assay was carried with FAT 40824/A according to OECD guideline 429 and EU method B.42. In order to study a possible contact allergenic potential of FAT 40824/A, three groups each of four female mice were treated daily with the test item at concentrations of 2.5 %, 5 % and 10 % in N,N-dimethylformamide (DMF) by topical application to the dorsum of each ear lobe (left and right) for three consecutive days. 10% was the highest technically applicable concentration in the vehicle. A control group of four mice was treated with the vehicle N,Ndimethylformamide (DMF) only. Five days after the first topical application the mice were injected intravenously into a tail vein with radio-labelled thymidine (3H-methyl thymidine).
Approximately five hours after intravenous injection, the mice were sacrificed, the draining auricular lymph nodes excised and pooled per group. Single cell suspensions of lymph node cells were prepared from pooled lymph nodes which were subsequently washed and incubated with trichloroacetic acid overnight. The proliferative capacity of pooled lymph node cells was determined by the incorporation of 3H-methyl thymidine measured in a ß scintillation counter.
All treated animals survived the scheduled study period. Neither clinical / local signs nor other findings were observed in any animals of the control group. On the second application day, the residual test item was found at both dosing sites in all mice of Group 2 (2.5%), Group 3 (5%) and Group 4 (10%), persisting for the remainder of the in-life phase of the study. The estimated concentration of test item required to produce a S.I. of 3 is referred to as the EC3 value. A test item is regarded as a sensitizer in the LLNA if the exposure to one or more test concentrations resulted in 3-fold or greater increase in incorporation of 3HTdR compared with concurrent controls, as indicated by the S.I.
In this study stimulation indices of 5.0, 3.1 and 4.7 were determined with the test item at concentrations of 2.5 %, 5 % and 10 %, respectively, in N,N-dimethylformamide (DMF). FAT 40824/A was therefore found to be a skin sensitizer in the LLNA.
Reference
No deaths occurred during the study period. Neither clinical / local signs nor other findings were observed in any animals of the control group. On the second application day, the residual test item was found at both dosing sites in all mice of Group 2 (2.5 %), Group 3 (5 %) and Group 4 (10 %), persisting for the remainder of the in-life phase of the study. The body weight of the animals, recorded prior to the first application and prior to necropsy, was within the range commonly recorded for animals of the strain and age.
The proliferative capacity of pooled lymph node cells was determined by the incorporation of 3H-methyl thymidine measured on a ß-scintillation counter.
|
Test item concentration (w/v) |
S.I. |
Group 2 |
2.5 |
5.0 |
Group 3 |
5 |
3.1 |
Group 4 |
10 |
4.7 |
An EC3 value could not be determined because this calculation requires a S.I. value of less than 3. |
CALCULATION AND RESULTS OF INDIVIDUAL DATA
The following results were obtained:
Vehicle: N,N-dimethylformamide (DMF)
Test item concentration (w/v) |
|
Measurement dpm |
Calculation |
Result |
||
dpm- BGa) |
number of lymph nodes |
dpm per lymph nodeb) |
S.I. |
|||
~ |
BGI |
25 |
~ |
— |
~ |
~ |
~ |
BGII |
26 |
— |
— |
— |
— |
~ |
CG1 |
1683 |
1657 |
8 |
207 |
— |
2.5 |
TG2 |
8257 |
8231 |
8 |
1029 |
5.0 |
5 |
TG3 |
5171 |
5145 |
8 |
643 |
3.1 |
10 |
TG4 |
7802 |
7776 |
8 |
972 |
4.7 |
BG = Background (1 ml 5 % trichloroacetic acid) in duplicate
CG = Control Group
TG = Test Item Group
S.I. = Stimulation Index
a) = The mean BG was calculated from the figures BG I and BG II values
b) = Since the lymph nodes of the animals of a dose group were pooled, dpm/node was
determined by dividing the measured value by the number of lymph nodes pooled
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed (sensitising)
- Additional information:
A GLP compliant LLNA assay was carried with FAT 40824/A according to OECD guideline 429 and EU method B.42. In order to study a possible contact allergenic potential of FAT 40824/A, three groups each of four female mice were treated daily with the test item at concentrations of 2.5 %, 5 % and 10 % in N,N-dimethylformamide (DMF) by topical application to the dorsum of each ear lobe (left and right) for three consecutive days.
All treated animals survived the scheduled study period. Neither clinical / local signs nor other findings were observed in any animals of the control group. On the second application day, the residual test item was found at both dosing sites in all mice of Group 2 (2.5%), Group 3 (5%) and Group 4 (10%), persisting for the remainder of the in-life phase of the study. The estimated concentration of test item required to produce a S.I. of 3 is referred to as the EC3value.A test item is regarded as a sensitizer in the LLNA if the exposure to one or more test concentrations resulted in 3-fold or greater increase in incorporation of 3HTdR compared with concurrent controls, as indicated by the S.I.
In this study stimulation indices of 5.0, 3.1 and 4.7 were determined with the test item at concentrations of 2.5 %, 5 % and 10 %, respectively, in N,N-dimethylformamide (DMF). FAT 40824/A was therefore found to be a skin sensitizer in the LLNA.
Respiratory sensitisation
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Based on the findings in the skin sensitisation study the test substance should be classified as Skin Sensitiser (Category 1) according to EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.